436 related articles for article (PubMed ID: 15752124)
1. Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces.
Chan AL; Juarez M; Allen R; Volz W; Albertson T
Photodermatol Photoimmunol Photomed; 2005 Apr; 21(2):72-8. PubMed ID: 15752124
[TBL] [Abstract][Full Text] [Related]
2. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study.
Taber SW; Fingar VH; Coots CT; Wieman TJ
Clin Cancer Res; 1998 Nov; 4(11):2741-6. PubMed ID: 9829737
[TBL] [Abstract][Full Text] [Related]
3. Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model.
Wong Kee Song LM; Wang KK; Zinsmeister AR
Cancer; 1998 Jan; 82(2):421-7. PubMed ID: 9445202
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy with mono-L-aspartyl chlorin e6 can cause necrosis of squamous cell carcinoma of tongue: experimental study on an animal model of nude mouse.
Kobayashi W; Liu Q; Nakagawa H; Sakaki H; Teh B; Matsumiya T; Yoshida H; Imaizumi T; Satoh K; Kimura H
Oral Oncol; 2006 Jan; 42(1):46-50. PubMed ID: 16266818
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
[TBL] [Abstract][Full Text] [Related]
6. Tissue distribution and photosensitizing properties of mono-L-aspartyl chlorin e6 in a mouse tumor model.
Gomer CJ; Ferrario A
Cancer Res; 1990 Jul; 50(13):3985-90. PubMed ID: 2354446
[TBL] [Abstract][Full Text] [Related]
7. Photofrin-mediated photodynamic therapy for treatment of aggressive head and neck nonmelanomatous skin tumors in elderly patients.
Gayl Schweitzer V
Laryngoscope; 2001 Jun; 111(6):1091-8. PubMed ID: 11404627
[TBL] [Abstract][Full Text] [Related]
8. Metabolic properties and photosensitizing responsiveness of mono-L-aspartyl chlorin e6 in a mouse tumor model.
Ferrario A; Kessel D; Gomer CJ
Cancer Res; 1992 May; 52(10):2890-3. PubMed ID: 1581904
[TBL] [Abstract][Full Text] [Related]
9. The effects of serum on cellular uptake and phototoxicity of mono-L-aspartyl chlorin e6 (NPe6) in vitro.
Sheyhedin I; Aizawa K; Araake M; Kumasaka H; Okunaka T; Kato H
Photochem Photobiol; 1998 Jul; 68(1):110-4. PubMed ID: 9679456
[TBL] [Abstract][Full Text] [Related]
10. Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessel constriction, vessel leakage, and tumor response.
McMahon KS; Wieman TJ; Moore PH; Fingar VH
Cancer Res; 1994 Oct; 54(20):5374-9. PubMed ID: 7923168
[TBL] [Abstract][Full Text] [Related]
11. Effects of photodynamic therapy using a fractionated dosing of mono-L-aspartyl chlorin e6 in a murine tumor.
Webber J; Leeson B; Fromm D; Kessel D
J Photochem Photobiol B; 2005 Feb; 78(2):135-40. PubMed ID: 15664500
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung.
Kato H; Furukawa K; Sato M; Okunaka T; Kusunoki Y; Kawahara M; Fukuoka M; Miyazawa T; Yana T; Matsui K; Shiraishi T; Horinouchi H
Lung Cancer; 2003 Oct; 42(1):103-11. PubMed ID: 14512194
[TBL] [Abstract][Full Text] [Related]
13. Photodynamic therapy of intestinal tumors with mono-L-aspartyl chlorin e6 (NPe6): a basic study.
Kikuchi T; Asakura T; Aihara H; Shiraki M; Takagi S; Kinouchi Y; Aizawa K; Shimosegawa T
Anticancer Res; 2003; 23(6C):4897-900. PubMed ID: 14981942
[TBL] [Abstract][Full Text] [Related]
14. Endovascular photodynamic therapy using mono-L-aspartyl-chlorin e6 to inhibit Intimal hyperplasia in balloon-injured rabbit arteries.
Nagae T; Aizawa K; Uchimura N; Tani D; Abe M; Fujishima K; Wilson SE; Ishimaru S
Lasers Surg Med; 2001; 28(4):381-8. PubMed ID: 11344521
[TBL] [Abstract][Full Text] [Related]
15. delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome.
Itkin A; Gilchrest BA
Dermatol Surg; 2004 Jul; 30(7):1054-61. PubMed ID: 15209801
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of topical delivery of mono-L-aspartyl chlorin e6 (NPe6): implication of topical NPe6-photodynamic therapy.
Wong TW; Aizawa K; Sheyhedin I; Wushur C; Kato H
J Pharmacol Sci; 2003 Oct; 93(2):136-42. PubMed ID: 14578580
[TBL] [Abstract][Full Text] [Related]
17. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial.
Morton C; Horn M; Leman J; Tack B; Bedane C; Tjioe M; Ibbotson S; Khemis A; Wolf P
Arch Dermatol; 2006 Jun; 142(6):729-35. PubMed ID: 16785375
[TBL] [Abstract][Full Text] [Related]
18. Outcome of photodynamic therapy using NPe6 for bronchogenic carcinomas in central airways >1.0 cm in diameter.
Usuda J; Ichinose S; Ishizumi T; Hayashi H; Ohtani K; Maehara S; Ono S; Honda H; Kajiwara N; Uchida O; Tsutsui H; Ohira T; Kato H; Ikeda N
Clin Cancer Res; 2010 Apr; 16(7):2198-204. PubMed ID: 20332318
[TBL] [Abstract][Full Text] [Related]
19. Optimization of treatment parameters for Foscan-PDT of basal cell carcinomas.
Betz CS; Rauschning W; Stranadko EP; Riabov MV; Albrecht V; Nifantiev NE; Hopper C
Lasers Surg Med; 2008 Jul; 40(5):300-11. PubMed ID: 18563776
[TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy of human squamous cell carcinoma in vitro and in xenografts in nude mice.
Megerian CA; Zaidi SI; Sprecher RC; Setrakian S; Stepnick DW; Oleinick NL; Mukhtar H
Laryngoscope; 1993 Sep; 103(9):967-75. PubMed ID: 8361317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]